Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

  • Founded: 2013
  • Location: Cambridge, MA
  • Employee range: 200 - 500
  • Clinical stage: COM
  • Therapy area: ALS
  • Drug types: NEU, GEN, PED, RAR
  • Lead product: Relyvrio (AMX0035)
  • Product link:
  • Funding: $246M stock Oct 2022; $190M IPO Jan 2022; $135M C Jul 2021; $30M B Jun 2020; $5M A Aug 2016; $3M Grant Jul 2016; $1.9M Nov 2015

job board

Short description:

Combination of existing products

Drug notes:

Also Clin2 PSP, Clin2 Wolfram syndrome, Clin2 Alzheimer's; AMX0114 Clin0 ALS, neurodegenerative diseases; undisclosed programs RD ALS, neurodegenerative diseases

Long description:

Amylyx is developing therapeutics for neurodegenerative disorders. A common feature of neurodegenerative diseases is neuronal death, which can be triggered when multiple stress factors are activated. Amylyx is identifying ways to preserve neurons by understanding the stress pathways that underlie Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. AMX0035, Amylyx’s lead program, has been shown in preclinical studies to protect neurons against death in a damage model by mitigating cellular stress and mitochondrial dysfunction. Following positive Phase 2 clinical results for ALS, AMX0035 is now being investigated in Phase 3 trials. Amylyx is also testing AMX0035 in patients with Alzheimer’s disease and Wolfram Syndrome.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy